PL413558A1 - Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this molecule - Google Patents
Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this moleculeInfo
- Publication number
- PL413558A1 PL413558A1 PL413558A PL41355815A PL413558A1 PL 413558 A1 PL413558 A1 PL 413558A1 PL 413558 A PL413558 A PL 413558A PL 41355815 A PL41355815 A PL 41355815A PL 413558 A1 PL413558 A1 PL 413558A1
- Authority
- PL
- Poland
- Prior art keywords
- molecule
- growth factor
- fibroblast
- modified
- modified molecule
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Cytokina czynnik wzrostu fibroblastów-1 (FGF-1), należy do dużej grupy białek liczącej 23 warianty o podobnej strukturze, pełniących pokrywające się, lecz nie identyczne funkcje. Pobudzają one podziały mitotyczne wielu typów komórek, spośród których najważniejsze to fibroblasty, komórki śródbłonka naczyń i keratynocyty. Przedmiotem zgłoszenia jest sztucznie skonstruowana cząsteczka FGF-1 trzeciej generacji o ulepszonych właściwościach biologicznych i strukturalnych oraz o dodatkowych właściwościach pozwalających na osiągnięcie przewagi technologicznej.The cytokine fibroblast growth factor-1 (FGF-1) belongs to a large group of proteins with 23 variants of a similar structure, which perform overlapping but not identical functions. They stimulate mitotic division of many types of cells, among which the most important are fibroblasts, vascular endothelial cells and keratinocytes. The subject of the application is an artificially constructed third generation FGF-1 molecule with improved biological and structural properties as well as additional properties enabling technological advantage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL413558A PL228868B1 (en) | 2015-08-13 | 2015-08-13 | Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this molecule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL413558A PL228868B1 (en) | 2015-08-13 | 2015-08-13 | Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this molecule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL413558A1 true PL413558A1 (en) | 2017-02-27 |
| PL228868B1 PL228868B1 (en) | 2018-05-30 |
Family
ID=58091997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL413558A PL228868B1 (en) | 2015-08-13 | 2015-08-13 | Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this molecule |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL228868B1 (en) |
-
2015
- 2015-08-13 PL PL413558A patent/PL228868B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL228868B1 (en) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014018630A2 (en) | bleaching of chondroitin sulfate glycans | |
| BR112018004536A2 (en) | cartilage addressing peptides | |
| BR112020026125A8 (en) | SUPERIOR OLIGONUCLEOTIDE OR 5'-CAP-TRINUCLEOTIDE COMPOUNDS AND THEIR USES IN RNA STABILIZATION, PROTEIN EXPRESSION AND IN THERAPY | |
| AR071479A1 (en) | RECOMBINANT STIMULANT FOLICLE HORMONE (RFSH) WITH SIALIC ACID UNION IN A2.3 AND A2.6 | |
| MX2019013982A (en) | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence. | |
| CO2019004006A2 (en) | Method to increase the secretion levels of interleukin 2 and its derived proteins | |
| CL2008001674A1 (en) | Simple variable domain (dab) of vascular endotlial growth anti-fator immunoglobulin (vegf); nucleoic acid that encodes it; vector and host cell; Method of production; antagonist of vegf comprising the dab; composition comprising the antagonist; and use of the antagonist to prepare a medication. | |
| BR112017027498A2 (en) | antibody, nucleic acid, compound, composition, and method for treating a patient with a disease. | |
| AR092188A1 (en) | HUMAN ANTIBODIES FOR GFRa3 AND METHODS FOR USE | |
| MX395421B (en) | ARTIFICIAL NUCLEIC ACID MOLECULES. | |
| BR112012024710A8 (en) | molecules that bind to the antigen, their production processes, as well as the pharmaceutical composition that comprise them | |
| BR112017007765A2 (en) | adenosine deaminase-2 (ada2) compositions, variants thereof and methods of using it | |
| BR112015031639A2 (en) | target integration | |
| EA201400871A1 (en) | METHOD OF DELIVERY OF NUCLEIC ACIDS WITH SEPARATION, THEIR COMPOSITIONS AND USE | |
| BR112017013956B8 (en) | Cytokine fusion proteins | |
| MX376623B (en) | METABOLICLY OPTIMIZED CELL CULTURE. | |
| BR112015026707A2 (en) | PPR PROTEIN E COMPLEX | |
| CL2022001655A1 (en) | Engineered variants of acid alpha-glucosidase. | |
| MX2021001305A (en) | Anti-cxcr2 antibodies and uses thereof. | |
| BRPI0813913A8 (en) | NUCLEIC ACID MOLECULE, RECOMBINANT NUCLEIC ACID SEQUENCE, HOST CELL, METHODS FOR PRODUCING RECOMBINANT HUMAN FSH, AND FOR PRODUCING THE HOST CELL, AND, USE OF A NUCLEIC ACID SEQUENCE. | |
| BR112018074304A2 (en) | nanoparticle compositions, kit and method for treating an individual with drug resistant cancer | |
| BR112018012070A2 (en) | method for the production of tissues / organs using blood cells | |
| CO2021005083A2 (en) | Miniaturized dystrophins and their uses | |
| Ushakov et al. | The decellularized cell-derived extracellular matrix enhances the paracrine function of human mesenchymal stromal/stem cells | |
| EA201891511A1 (en) | ANALOGUES OF CORTISTATIN AND THEIR APPLICATIONS |